Once deruxtecan is released in the HER2-positive cancer cell, it can diffuse out of the cell and can have a cytotoxic effect on surrounding HER2-negative tumor cells and on the tumor microenvironment, a characteristic known as “bystander effect” [13]. The gene discussed is ERBB2; the disease is neoplasm.